Affiliation:
1. Department of Physiology, Faculty of Medicine, Fırat University, Elazig, Turkey
Abstract
The aim of this study was to compare the levels of nesfatin-1 in healthy subjects with those in prediabetic and diabetic patients who have different glucose tolerance levels. Overall, 100 subjects were divided into 5 groups healthy control (C), impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), metabolic syndrome (MS) and type 2 diabetes mellitus, (Type 2 DM). Glycated hemoglobin (HbA1c) assessed the glycemic control. Homeostasis model assessment of insulin resistance (HOMA-IR) was determined using computer analyses. Nesfatin-1 levels were measured using ELISA method. IFG and IGT (prediabetic groups) from MS and Type 2 DM (diabetic groups) differed significantly in HOMA-IR. The nesfatin-1 levels were lower, although not statistically significant, in IFG (0.937±0.03 ng/ml, p=0.07) and IGT (1.039±0.06 ng/ml, p=0.5) groups compared to healthy subjects (1.094±0.07 ng/ml). However, the nesfatin-1 levels were lower in patients with Type 2 DM (0.867±0.02 ng/ml, p=0.007) and MS (0.885±0.01 ng/ml, p=0.01) compared to healthy subjects. Nesfatin-1 levels were significantly lower in diabetic patients compared to healthy subjects. This study supports the role of insulin resistance in decreased nesfatin-1 levels in patients with Type 2 DM and MS.
Publisher
Institute of Physiology of the Czech Academy of Sciences
Subject
General Medicine,Physiology
Reference29 articles.
1. ABACI A, CATLI G, ANIK A, KUME T, BOBER E: The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr Diabetes 14: 189-195, 2013.
2. ABDUL-GHANI MA, TRIPATHY D, DEFRONZO RA: Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29: 1130-1139, 2006.
3. AKSU O, AYDIN B, DOGUC DK, ILHAN I, OZTURK O, ALTUNTAS A, DEMIRKAN H, KOROGLU BK, TAMER MN: The evaluation of nesfatin-1 levels in patients with OSAS associated with metabolic syndrome. J Endocrinol Invest 38: 463-469, 2015.
4. ALGUL S, ERMAN F, KARA B, KARA M, ERMAN O: The effect of short-term antidepressant treatment on serum levels of nesfatin-1, nitric oxide and ghrelin in patients with major depressive disorder. F U Med J Health Sci 27: 69-73, 2013.
5. ANWAR GM, YAMAMAH G, IBRAHIM A, EL-LEBEDY D, FARID TM, MAHMOUD R: Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. Regul Pept 188: 21-24, 2014.
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献